European Medicines Agency Recommends Six New Medicines for Approval, Including for Pancreatic Cancer and Weight Management

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for approval at its October 2026 meeting. These include Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma, Foundayo (orforglipron) as an oral GLP-1 receptor agonist for weight management and type 2 diabetes, and Yuviwel (navepegritide) for achondroplasia in children. Additionally, Kizfizo (temozolomide) was recommended for glioblastoma multiforme and malignant glioma, and two biosimilar medicines, Fovlussea (ranibizumab) and Neuzafy (filgrastim), received positive opinions. The CHMP also recommended TRYNGOLZA (olezarsen) for severe hypertriglyceridemia.